Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Schering AG acquires Japanese and Asian rights to Campath

Feb. 7, 2003

Revimid granted fast track designation for relapsed or refractory multiple myeloma

Feb. 6, 2003

ALVAC-CEA/B7.1 under investigation in two colorectal cancer trials

Feb. 4, 2003

Recent developments at Seattle Genetics

Feb. 4, 2003

Phase I results for trastuzumab with IL-2 in nonhematological cancer

Feb. 4, 2003

AlphaRx acquires exclusive rights to VT-1

Jan. 30, 2003

Canvaxin receives fast track designation for metastatic melanoma

Jan. 29, 2003

HuMax-CD4 enters phase II clinical studies for CTCL

Jan. 28, 2003

Rights to cantuzumab mertansine returned to ImmunoGen

Jan. 28, 2003

Single-agent epratuzumab trial closes

Jan. 28, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 4, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...